Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...

Only one state has disability coverage parity, in which mental health conditions are covered in the same way as physical ...

SPL-026 is under development for the treatment of major depressive disorder (MDD). The drug candidate is a psychedelic N,N-dimethyltryptamine (DMT) based medicine. It is administered through i ...

Mysuru: One in three women in rural areas are suffering from stress, depression, and anxiety in Chamarajanagar and Chitradurga, according to the findi.

People explore different treatments and therapies to help with depression, and recently, researchers wanted to understand if ...

From 2017 to 2021, pediatric depression and anxiety rates increased by 55.6% and 31.1%, respectively. Rates were higher ...

Lysergic acid diethylamide is under clinical development by Mind Medicine MindMed and currently in Phase II for Major Depressive Disorder.

Because of rising rates of anxiety, depression and other mental health concerns among adolescents ... Transcranial magnetic ...

Even though there are now many ways to communicate through technology, I still believe that handwritten letters remain an ...

Short, dark days may leave you prone to vitamin D deficiency and seasonal affective disorder. If your doctor determines you ...

MindMed currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the biotech sector are Castle Biosciences, Inc. CSTL, CytomX Therapeutics CTMX and Spero Therapeutics SPRO, each ...

P rogress in addressing mental health is notoriously slow and mostly incremental. Breakthrough treatments tend to be rare, ...